Difference of biological activities and signals between IFN-ζ/limitin and IFN-α
Difference of biological activities and signals between IFN-ζ/limitin and IFN-α
批准号:
15390300
负责人:
ORITANI Kenji
金额:
$9.47万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Our identified limitin has a sequence homology with type I IFNs and displays antiviral activity against several viruses. In addition, it can bind to IFN-α/βR and induces some effectors as IFN-α and IFN-β. Based on these facts, limitin has been considered as a novel type I IFN with the designation of IFN-ζ by the Nomenclature Committee of the International Society for Interferon and Cytokine Research. Both IFN-ζ/limitin and IFN-α were titrated with a cytopathic effect dye binding assay in encephalo myocarditis virus-infected L929 cells. Half-maximal protection was achieved with 30 pg/ml of IFN-ζ/limitin and with 30-300 pg/ml of several subtypes of IFN-αs. These titrated IFNs were used for point-by-point comparison of their biological activities and signals. IFN-ζ/limitin showed antitumor, immunomodulatory, and antiviral activities as strong as IFN-α. However, IFN-ζ/limitin did not suppress CFU-GM or BFU-E colony formation while IFN-α did. Much higher concentrations of IFN-ζ/limitin than … More IFN-α were required for the suppression of CFU-IL7 and CFU-Meg colony formation. Similarly, approximately 30% of CFU-GM and 50% of BFU-E in bone marrow were reduced when 4,000 international unit (IU)/body/day of IFN-α was injected, while there was no influence on these progenitors even when IFN-ζ/limitin was injected at 40,000 IU/body/day. With regard to signaling, similar signaling molecules are used between IFN-ζ/limitin and IFN-α, but there are some differences. In fibroblasts, IRF-1-dependent pathway is more critical for IFN-ζ/limitin than IFN-α to induce antiviral state and to induce ISRE promoter activity. In addition, higher dose of IFN-ζ/limitin is required for the induction of Daxx in megakaryocytes than IFN-α. We also analyzed a role of Daxx in apoptosis, in addition, identified DMAP1 and TSG101 as novel Daxx-associated proteins. As described above, we have clarified characters of IFN-ζ/limitin in biological activities and signaling. To our regret, we could not isolate the human homologue of IFN-ζ/limitin. To make an engineered cytokine with some features of IFN-ζ/limitin, we have constructed IFN-a cDNA with mutations based on the differences of sequence between IFN-ζ/limitin and IFN-α. Less
期刊论文(60)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1128/jvi.77.17.9622-9631.2003
发表时间:
2003-09-01
期刊:
JOURNAL OF VIROLOGY
影响因子:
5.4
作者:
[Kawamoto, SI, Oritani, K, Matsuzawa, Y]
通讯作者:
Matsuzawa, Y
Interferon-zeta/limitin : novel type I interferon that displays a narrow rane of biological activity.
Interferon-zeta/limitin:新型 I 型干扰素,具有窄范围的生物活性。
DOI:
--
发表时间:
2004
期刊:
Int J Hematol. 80
影响因子:
--
作者:
[Oritani K, et al.]
通讯作者:
et al.
DOI:
10.1016/j.bbrc.2004.02.126
发表时间:
2004-04
期刊:
Biochemical and biophysical research communications
影响因子:
3.1
作者:
[R. Muromoto;K. Sugiyama;Tetsuya Yamamoto;K. Oritani;Kazuya Shimoda;T. Matsuda]
通讯作者:
R. Muromoto;K. Sugiyama;Tetsuya Yamamoto;K. Oritani;Kazuya Shimoda;T. Matsuda
Physical and functional interactions between Daxx and DNA methyltransferase1-accociated protein, DMAP1.
Daxx 和 DNA 甲基转移酶 1 相关蛋白 DMAP1 之间的物理和功能相互作用。
DOI:
--
发表时间:
2004
期刊:
J Immunol. 172
影响因子:
--
作者:
[Azuma T, et al., Muromoto R et al., Saida T., Muromoto R et al.]
通讯作者:
Muromoto R et al.
Limitin an interferon-like cytokine, transduces inhibitory signals on B-cell growth through activation of Tyk2, but not Stat1, followed by induction and nuclear translocation of Daxx.
Limitin 是一种干扰素样细胞因子,通过激活 Tyk2(而非 Stat1)转导 B 细胞生长的抑制信号,然后诱导 Daxx 并进行核易位。
DOI:
--
发表时间:
2003
期刊:
Exp Hematol. 31
影响因子:
--
作者:
[Aoki K, et al.]
通讯作者:
et al.
共 24 条
Analysis of in vivo effects of possible immune regulatory moleculesfor artificial management of immune systems
-
批准号:22591062
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.75万
-
财政年份:2010
-
负责人:ORITANI Kenji
-
依托单位:
Development of a novel interferon with mild adverse effects
-
批准号:19390264
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.98万
-
财政年份:2007
-
负责人:ORITANI Kenji
-
依托单位:
Establishment of a novel IFN therapy with little side effects
-
批准号:17390277
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.86万
-
财政年份:2005
-
负责人:ORITANI Kenji
-
依托单位:
Biological activity of limitin and adiponectin
-
批准号:13671064
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.56万
-
财政年份:2001
-
负责人:ORITANI Kenji
-
依托单位:
Clinical application of limitin that has anti-tumor and anti-viral activity
-
批准号:13557081
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.9万
-
财政年份:2001
-
负责人:ORITANI Kenji
-
依托单位:
海外基金